Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DDT | P30046 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754710 | 0.90 | ELANE (0.67) | ELANETP53SMN1; SMN2NOTUMCCR1 | |
| SCHEMBL5757507 | 0.89 | ELANE (0.66) | ELANETP53NOTUMCCR1MEN1 | |
| SCHEMBL5759366 | 0.88 | ELANE (0.65) | ELANETP53NOTUMCCR1ALDH1A1 | |
| SCHEMBL5755122 | 0.87 | ELANE (0.67) | ELANETP53NOTUMCCR1NPY5R | |
| SCHEMBL5757528 | 0.87 | ELANE (0.63) | ELANETP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5755788 | 0.86 | ELANE (0.79) | ELANESMN1; SMN2NOTUMCCR1HTT | |
| SCHEMBL5759291 | 0.85 | ELANE (0.78) | ELANESMN1; SMN2NOTUMCCR1ALDH1A1 | |
| SCHEMBL5755815 | 0.85 | ELANE (0.61) | ELANETP53SMN1; SMN2CCR1MEN1 | |
| SCHEMBL5759261 | 0.84 | ELANE (0.70) | ELANESMN1; SMN2NOTUMCCR1MEN1 | |
| SCHEMBL5931075 | 0.84 | ELANE (0.65) | ELANETP53SMN1; SMN2NOTUMCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885TP53 3353/4885SMN1; SMN2 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.